Milind Subhash Pakle

Milind Subhash Pakle

Active Director Director DIN 05200698
DIN 05200698 First appointment Mar 2012 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 4 historical roles
Total affiliations 7 Since Mar 2012
Shareholding value •••• Premium profile

About Milind Subhash Pakle

Data last updated:

Milind Subhash Pakle is a Director at Healzen Research Private Limited (since 2024), Director at Healzen Quantum Cure Private Limited (since 2024) and Designated Partner at Blue Lotus Cap Management Llp (since 2024). The companies operate in Healthcare, Business Outsourcing and Information Technology. The largest current company by reported revenue is Healzen Research Private Limited at ₹1.9 Lakh (FY 2025). Earlier, Milind Subhash Pakle was a Director at Liticap Private Limited (2017–2018) and Director at Valued Online Services Private Limited (2015–2017) and 2 more.

DIN 05200698
Primary Designation Director
Industry Healthcare
First Appointment 27 Mar 2012
Oldest Company Age 11 yrs
Largest company Healzen Research Private Limited · ₹1.9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Healzen Research Private Limited U86201PN2024PTC227733
Director01 Apr 20242024₹1.9 Lakh (FY 2025)Active
Healzen Quantum Cure Private Limited U86201MH2024PTC418884
Director01 Apr 20242024Active
Designated Partner02 Feb 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Liticap Private Limited U74110MH2010PTC200663
Director28 Jun 20172010Active
Director05 May 20152015₹1.9 Lakh (FY 2025)Active
Sunmukh Healthcare Private Limited U93000MH2012PTC228705
Director27 Mar 20122012Strike Off
Designated Partner11 Apr 20152015Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Ekam Consulting Llp
Healzen Research Private Limited
Healzen Quantum Cure Private Limited
Blue Lotus Cap Management Llp
Premium access

Shareholding and investment profile for Milind Subhash Pakle

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Milind Subhash Pakle

Milind Subhash Pakle currently holds 3 directorships: Healzen Research Private Limited (Director, since 01 Apr 2024, revenue ₹1.9 Lakh (FY 2025)); Healzen Quantum Cure Private Limited (Director, since 01 Apr 2024); Blue Lotus Cap Management Llp (Designated Partner, since 02 Feb 2024).

Milind Subhash Pakle was first appointed on 27 Mar 2012 as Director at Sunmukh Healthcare Private Limited. The most recent appointment on record is 01 Apr 2024 at Healzen Quantum Cure Private Limited.

Milind Subhash Pakle held 4 earlier board appointments: Liticap Private Limited (Director, 28 Jun 2017 to 22 Jan 2018); Valued Online Services Private Limited (Director, 05 May 2015 to 16 Jun 2017); Sunmukh Healthcare Private Limited (Director, 27 Mar 2012 to 25 Apr 2012); Ekam Consulting Llp (Designated Partner, from 11 Apr 2015).

The current boards of Milind Subhash Pakle's companies include Apurva Nilesh Ahirrao (Healzen Research Private Limited), Deepak Premanand Patkar (Healzen Research Private Limited), Mahesh Babanrao Bhalerao (Healzen Research Private Limited), Prakash Sakharam Kalke (Healzen Research Private Limited), Ramesh Shantaram Pakle (Blue Lotus Cap Management Llp).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available